Short Communication

Higher Vessel Densities in Retinoblastoma with Local Invasive Growth and Metastasis

Jochen Rössler,* Torsten Dietrich,* Helena Pavlakovic,* Lothar Schweigerer,* Werner Havers,* Andreas Schüler,[†] Norbert Bornfeld,[†] and Harald Schilling[†]

From the Department of Pediatric Hematology, Oncology and Endocrinology,* and the Department of Ophthalmology,[†] University Hospital of Essen, Essen, Germany

In this study, the importance of angiogenesis (the growth of new blood vessels from existing ones) for the growth of retinoblastoma was investigated by a retrospective immunohistochemical analysis. An individual vessel index for each tumor was determined using the endothelial-specific antibody CD 31 for vessel staining. The obtained data were correlated with clinical features, pathohistological characteristics, and the presence of metastasis. In 107 retinoblastomas collected between 1980 and 1990, we found no difference in the vessel densities between uni- and bilateral retinoblastomas (P = 0.41). However, tumors that had invaded the chorioid and/or the optic nerve statistically showed higher vessel densities than tumors without local invasive growth (P = 0.05and P = 0.024). A tendency of higher vessel densities in retinoblastomas presenting with metastasis at the time of diagnosis was observed (P = 0.11). Based on this observation, we proceeded to examine all retinoblastomas presenting with metastasis at the time of diagnosis. These included patients that were treated between 1968 and 1993. The 18 investigated retinoblastomas had significantly higher vessel densities than all other retinoblastomas presenting without metastasis (P = 0.025). Our data indicate that in retinoblastoma, blood vessels are essential for local and systemic invasive growth. Therefore, an anti-angiogenic therapy could be considered in the multimodal therapy concept for retinoblastomas with invasive growth, both locally and systemically. (Am J Pathol 2004, 164:391–394)

Retinoblastoma is the most frequent ophthalmic tumor in childhood.^{1–3} One or both eyes could be affected. Reti-

noblastomas can harbor the classical mutation of the retinoblastoma tumor suppressor gene.⁴ Retinoblastomas are thought to develop from immature neuroectodermal cells of the retina.⁵ Most children become symptomatic with signs of amblyopia or a typical light reflection in the affected eye. Early diagnosis can lead to an excellent outcome with a multimodal therapy concept consisting of chemoreduction, cryo-, laser- or brachytherapy, external beam radiation or enucleation.⁶ However, patients initially presenting with metastasis have a poor prognosis.⁷

Retinoblastomas can show endophytic or exophytic growth, sometimes with signs of invasiveness. Tumor cells can invade the choroid or the optic nerve. If the sclera or the lamina cribrosa is invaded, extraocular growth has occurred. By such continual growth, tumor cells can spread to the brain, the surrounding head bones, or soft tissues. In rare cases, retinoblastoma can disseminate in the whole body and form metastasis in the bone marrow, the liver, or the skeletal system. Invasion of the choroid or the optic nerve are risk factors for developing such metastases.^{8,9}

Tumor growth and the formation of hematogenous metastasis depend on angiogenesis.¹⁰ The expansion of tumors beyond the size of a few millimeters in diameter, requires the induction of new capillaries. This neovascularization is believed to be mediated by angiogenic stimulators produced and released by stromal cells or tumor cells themselves.¹¹ Numerous studies have demonstrated that the vascular density of a tumor correlates with metastasis and poor outcome.^{12–15} The importance of angiogenesis for the growth of retinoblastomas has not yet been demonstrated. The expression of angiogenic factors such as VEGF and bFGF have been found, implicating a possible angiogenic potential of retino-

Supported by the Faculty of Medicine of the University of Essen (IFORES) and Deutsche Leukämie-Forschungshilfe.

Accepted for publication November 3, 2003.

Present address for J.R. is Clinic IV, Pediatric Hematology, Oncology, University Hospital of Freiburg, 79106 Freiburg, Germany.

Present address for H.P. and L.S. is Department of Pediatrics 1, Children's Hospital, University of Göttingen, 37075 Göttingen, Germany.

Address reprint requests to Jochen Rössler, Clinic IV: Pediatric Hematology, Oncology, University Hospital of Freiburg, 79106 Freiburg, Germany. E-mail: roessler@kikli.ukl.uni-freiburg.de.

| Age median | Unilateral bilateral n (%) | No invasion n (%) | Local invasion (choroidea, opticus) n (%) | Extraorbital growth n (%) | Metastasis n (%) |
|---------------|-------------------------------|----------------------|---|---------------------------------|---------------------|
| 19 months | 52 (49%) 55 (51%) | 55 (51%) | 52 (49%) | 7 (7%) | 6 (6%) |

Table 1. Pathohistological Characteristics of 107 Retinoblastomas Examined

blastomas.^{16,17} In the present study, we have quantified vessels in retinoblastoma tissue with different clinical characteristics and pathohistological features. Our intention in this study was to define the role of angiogenesis in retinoblastomas with regard to invasion and the formation of metastasis. Based on these data one could discuss the possibility of anti-angiogenic therapy in the future.

Materials and Methods

Patients

Between the years 1980 and 1990, 320 eyes were enucleated due to retinoblastoma at our Department of Ophthalmology. Only sections of paraffin-embedded eyes with adequate tumor material to perform immunohistochemical staining were accepted for the study. A total of 107 enucleated eyes with retinoblastomas met this criterion.

For the second part of the study, 30 patients presenting with metastasized retinoblastomas at our Center between 1968 and 1993 were selected. A total of 18 enucleated eyes with retinoblastomas were available for immunohistochemistry.

Immunohistochemistry

Five-micron paraffin sections were stained for tumor vessels with a CD31 antibody (Dako, Copenhagen, Denmark) using an avidin-biotin immunoperoxidase technique, as previously described.¹⁸ Hematoxylin and eosin staining was performed in parallel. Hot spots, areas with the richest vascularity, were chosen at low magnification (×40). Then the CD31-positive vessels were counted using an eyepiece with a square field of 0.25 mm² at a higher magnification (×200). Three hot spots were counted for each tumor independently by two examiners blinded to the clinical and pathohistochemical data. The median of the three counts was recorded. The interobserver counting variability was less than 5%.

Statistical Analysis

Statistical analysis was performed using SPSS 6.01 software (SPSS, Inc., Chicago, IL). The Cox proportional hazards model was applied to select prognostic factors. A P value of less than 0.05 was considered statistically significant.

Results

Initially, a total of 107 retinoblastoma sections were examined. Clinical and pathohistological characteristics are listed in Table 1. Patients presenting with unilateral and




Figure 1. Immunohistochemical staining for endothelial cells with CD31 antibody in retinoblastoma. **a:** Poorly vascularized tumor. **b:** Well vascularized tumor. **c:** Tumor with very exceptionally high number of vessels. Peroxidase, magnification: ×200.




Figure 2. Comparison of vessel densities per 0.25-mm² field. **a:** Unilateral *versus* bilateral. **b:** No local invasive growth *versus* invasive (choroid or optic nerve involvement, and both choroid and optic nerve involvement). **c:** No metastasis *versus* metastasis.

bilateral retinoblastomas were included. According to the pathohistological growth pattern, the tumors were evaluated for their invasive growth. The infiltration of the choroid and/or invasion into the optic nerve was defined as local invasive growth. A further criterion was the presence of metastasis at the time of diagnosis.

Endothelial cells were stained with a CD31 antibody and vessels were counted according to the international consensus on the methodology and criteria of quantification of angiogenesis in solid tumors.¹⁸ A variation of vessel lumen was not observed and the distribution of the vessels in the retinoblastoma showed no particular pattern. Retinoblastomas with scarce and with numerous vessels could be identified (Figure 1, a and b). One retinoblastoma with a very exceptionally high number of vessels could be observed (Figure 1c). Unilateral and bilateral retinoblastomas did not show differences in their median vessel count (unilateral x = 4.6; bilateral x = 4.8; P = 0.41) (Figure 2a). The same was the case with other clinical data, such as age at the time of diagnosis, and sporadic or familial retinoblastoma (data not shown). Local invasiveness ie, retinoblastomas infiltrating the choroid or the optic nerve or both, correlated with higher vessel densities (no local invasiveness, x = 4.1; invasion of choroid or optic nerve, x = 5.1, P = 0.05; invasion of choroid and optic nerve, x = 5.3; P = 0.024) (Figure 2b). When we studied the vascular indices of retinoblastomas presenting with metastasis, we noted a two-fold higher vascular density. This observation was however statistically insignificant (metastasis, x = 10.5; no metastasis, x = 4.7; P = 0.11) (data not shown). The number of patients presenting with metastasis being small (n = 6)possibly plays a role for the insignificant result in the statistical tests. To further investigate the possible correlation between higher vessel densities and the presence of metastasis, we examined all tumors (n = 18) available from retinoblastoma patients presenting with metastasis at the time of diagnosis at our Center between 1968 and 1993. The metastasized retinoblastomas had significantly higher vessel densities than all retinoblastomas presenting without metastasis (metastasis, x = 7.7; P = 0.025) (Figure 2c).

In conclusion, our study demonstrates for the first time that vessel densities in retinoblastoma correlate with local invasive growth and the presence of metastasis at the time of diagnosis. Therefore, in retinoblastoma, angiogenesis seems to play an important role for invasive growth, both locally and systemically.

Discussion

The survival rate of retinoblastoma patients has dramatically improved over the last century. It is now greater than 90% in major centers, while untreated tumors are still mostly fatal.¹⁹ Early diagnosis and improved treatment methods are mostly responsible for the improved survival. However, patients from countries with insufficient health care and diagnostic tools still often present with disseminated disease. Such advanced tumors are often not curable with the available multimodal therapy. The survival rate in the cases with presence of metastasis is 30%. The presence of metastasis is, therefore, an important feature in the outcome of retinoblastoma. Risk factors for metastasis in retinoblastomas have been studied by several authors. Pathohistological signs of invasion of eye structures such as the choroid, sclera, and optic nerve anterior or posterior to the lamina cribrosa are highly predictive for the presence of metastasis and correlate with the risk of death.²⁰ In such patients, prophylactic orbital external beam radiotherapy and/or systemic chemotherapy may be indicated. Several studies on patients with metastasis show that high-dose chemotherapy with autologous bone marrow rescue is a therapeutic option, but nevertheless the prognosis is very poor.^{21,22} Data on biological factors influencing the difference in aggressiveness and invasive potential of retinoblastoma are scarce. The biological phenomenon of tumor angiogenesis as an indication of higher malignant potential has been shown on multiple occasions with solid neoplasms.^{12–15} In our study, we were interested in whether vessel densities, as an indicator of tumor angiogenesis, play a role in invasive growth of retinoblastomas and the formation of metastasis. If this were the case, anti-angiogenesis could be discussed as a new therapeutic option.

We did not find a difference in vessel densities when clinical data, such as uni- or bilateral retinoblastoma, familial or sporadic cases, sex or age were examined. The first important result of this study shows that the number of intratumoral vessels plays a significant role in local invasive growth. Retinoblastomas are usually detected by fundoscopy at a very early stage when local structures are not invaded by the tumor cells. We speculate that the angiogenic switch,²³ which renders the tumor a highly vascularized phenotype, occurs at the stage when the choroid or the optic nerve are infiltrated. In such cases, as shown by our data, angiogenesis seems to play a crucial role for the further expansion. The second important result of our study is that intratumoral vessel densities are a statistically significant factor for the hematogenous metastasizing of retinoblastomas. Once tumor cells have gained access to the circulation, they can colonize to distant sites. Therefore, retinoblastomas with high vessel counts indicate a high risk of developing hematogenous metastasis. As a consequence, in such patients a specific diagnostic and staging program should be initiated to identify metastasis.

Anti-angiogenesis as a new treatment option has been tested for several tumors including pediatric malignancies.^{24,25} Based on current knowledge, it is believed that patients would profit most from a combination therapy consisting of anti-angiogenic and chemotherapeutic drugs. Such a combination therapy targets both the endothelial compartment and the tumor cell compartment, and seems to be more effective in improving the outcome than either therapy alone.

Retinoblastomas with pathohistological signs of invasiveness are at risk of having metastasized. In regard to our data, tumors additionally demonstrating high vessel densities could profit from an anti-angiogenic treatment. In these rare cases the additional application of anti-angiogenic substances in combination with a chemotherapeutical regime seems to be justified, since we have shown that angiogenesis is an important feature in these tumors.

References

- Kock E, Naeser P: Retinoblastoma in Sweden 1958–1971: a clinical and histopathological study. Acta Ophthalmol Copenh 1979, 57:344–350
- Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H: The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990, 97:1143–1147
- Sanders BM, Draper GJ, Kingston JE: Retinoblastoma in Great Britain 1969–80: incidence, treatment, and survival. Br J Ophthalmol 1988, 72:576–583
- Hinds PW: The retinoblastoma tumor suppressor protein. Curr Opin Genet Dev 1995, 5:79–83
- Tso MOM, Zimmermann LE, Fine BS: The nature of retinoblastoma II: photoreceptor differentiation: an electron microscopy study. Am J Ophthalmol 1970, 69:350–359
- Bornfeld N, Schüler A, Bechrakis N, Henze G, Havers W: Preliminary results of primary chemotherapy in retinoblastoma. Klin Pädiatr 1997, 209:216–221
- Messmer EP, Heinrich T, Hopping W, de Sutter E, Havers W, Sauerwein W: Risk factors for metastasis in patients with retinoblastoma. Ophthalmology 1991, 99:136–141
- Shields C, Shields JA, Baez KA, Cater J, De Potter PV: Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Ophthalmol 1993, 77:544–548
- Shields C: Optic nerve invasion of retinoblastoma: metastatic potential and clinical risk factor. Cancer 1994, 73:692–698
- Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58–61
- Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757–1763
- Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL: Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patient. J Natl Cancer Inst 1997, 89:1044–1049
- Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A, Matsuyama K, Muraoka R: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997, 57:1043–1046
- Meitar D, Crawford SE, Rademaker AW, Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996, 14:405–414
- Foss AJE, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S: Microvessel count predicts survival in uveal melanoma. Cancer Res 1996, 56:2900–2903
- Pe'er J, Neufeld M, Baras M, Gnessin H, Itin A, Keshet E: Rubeosis iridis in retinoblastoma: histologic findings and the possible role of vascular endothelial growth factor in its induction. Ophthalmology 1997, 104:1251–1258
- Schweigerer L, Neufeld G, Gospodarowicz D: Basic fibroblast growthfactor is present in cultured human retinoblastoma cells. Invest Ophthalmol Vis Sci 1987, 28:1838–1843
- Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY: Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 14:2474–2484
- Höpping W, Havers W, Passarge E: Retinoblastom. Pädiatrie in Praxis und Klinik. Edited by KD Bachmann. New York. Georg Thieme Verlag, Gustav Fischer Verlag, 1988, pp 755–770
- Olver J, McCartney ACE, Kingston J, Hungerford J: Histological indicators of the prognosis for survival following enucleation for retinoblastoma. Tumors of the Eye. Edited by N Bornfeld, ES Gragoudas, W Höpping, PK Lommatzsch. New York: Kugler, 1991, pp 59–67
- Saleh R, Gross S, Cassano W, Gee A: Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer 1988, 62:2301–2303
- Sandri A, Besenzon L, Acquaviva A, Marino C, Cordero di Montezemolo L, Madon E: "Eight drugs in one day" chemotherapy in a nonfamilial bilateral retinoblastoma with recurrent cerebrospinal fluid metastasis. Pediatr Hematol Oncol 1998, 15:557–561
- Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353–364
- 24. Schweigerer L: Anti-angiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995, 73:497–508
- Pavlakovic H, Havers W, Schweigerer L: Multiple angiogenesis stimulators in a single malignancy. Angiogenesis 2001, 4:259–262